QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

This Article Full Text (PDF) Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Heuring, R. E. Articles by Peroutka, S. J. Search for Related Content PubMed PubMed Citation Articles by Heuring, R. E. Articles by Peroutka, S. J.

 Previous Article  |  Next Article 

Journal of Neuroscience, Vol 7, 894-903, Copyright © 1987 by Society for Neuroscience

ARTICLE

Characterization of a novel 3H-5-hydroxytryptamine binding site subtype in bovine brain membranes

RE Heuring and SJ Peroutka

3H-5-Hydroxytryptamine (5-HT) binding sites were analyzed in bovine brain membranes. The addition of either the 5-HT1A-selective drug 8-OH- DPAT (100 nM) or the 5-HT1C-selective drug mesulergine (100 nM) to the assay resulted in a 5-10% decrease in specific 3H-5-HT binding. Scatchard analysis revealed that the simultaneous addition of both drugs decreased the Bmax of 3H-5-HT binding by 10-15% without affecting the KD value (1.8 +/- 0.3 nM). Competition studies using a series of pharmacologic agents revealed that the sites labeled by 3H-5-HT in bovine caudate in the presence of 100 nM 8-OH-DPAT and 100 nM mesulergine appear to be homogeneous. 5-HT1A selective agents such as 8- OH-DPAT, ipsapirone, and buspirone display micromolar affinities for these sites. RU 24969 and (-)pindolol are approximately 2 orders of magnitude less potent at these sites than at 5-HT1B sites which have been identified in rat brain. Agents displaying nanomolar potencies for 5-HT1C sites such as mianserin and mesulergine are 2-3 orders of magnitude less potent at the 3H-5-HT binding sites in bovine caudate. In addition, both 5-HT2- and 5-HT3-selective agents are essentially inactive at these binding sites. These 3H-5-HT sites display nanomolar affinity for 5-carboxyamidotryptamine, 5-methoxytryptamine, metergoline, and 5-HT. Apparent Ki values of 10-100 nM are obtained for d-LSD, RU 24969, methiothepin, tryptamine, methysergide, and yohimbine, whereas I-LSD and corynanthine are significantly less potent. In addition, these 3H-5-HT labeled sites are regulated by guanine nucleotides and calcium. Regional studies indicate that this class of sites is most dense in the basal ganglia but exists in all regions of bovine brain. These data therefore demonstrate the presence of a homogeneous class of 5-HT1 binding sites in bovine caudate that is pharmacologically distinct from previously defined 5-HT1A, 5-HT1B, 5- HT1C, 5-HT2, and 5-HT3 receptor subtypes. We therefore suggest that this class of sites be designated the 5-HT1D subtype of binding sites labeled by 3H-5-HT.

This article has been cited by other articles:

				V. Contesse, S. Lenglet, L. Grumolato, Y. Anouar, I. Lihrmann, H. Lefebvre, C. Delarue, and H. Vaudry Pharmacological and Molecular Characterization of 5-Hydroxytryptamine7 Receptors in the Rat Adrenal Gland Mol. Pharmacol., September 1, 1999; 56(3): 552 - 561. [Abstract] [Full Text]

				G. Pineyro and P. Blier Autoregulation of Serotonin Neurons: Role in Antidepressant Drug Action Pharmacol. Rev., September 1, 1999; 51(3): 533 - 591. [Abstract] [Full Text] [PDF]

				J. De Vry, R. Schohe-Loop, H.-G. Heine, J. M. Greuel, F. Mauler, B. Schmidt, H. Sommermeyer, and T. Glaser Characterization of the Aminomethylchroman Derivative BAY × 3702 as a Highly Potent 5-Hydroxytryptamine1A Receptor Agonist J. Pharmacol. Exp. Ther., March 1, 1998; 284(3): 1082 - 1094. [Abstract] [Full Text]

				J. M. Loudon, S. M. Bromidge, F. Brown, M. S. G. Clark, J. P. Hatcher, J. Hawkins, G. J. Riley, G. Noy, and B. S. Orlek SB 202026: A Novel Muscarinic Partial Agonist with Functional Selectivity for M1 Receptors J. Pharmacol. Exp. Ther., December 1, 1997; 283(3): 1059 - 1068. [Abstract] [Full Text]

				H. Schoemaker, Y. Claustre, D. Fage, L. Rouquier, K. Chergui, O. Curet, A. Oblin, F. Gonon, C. Carter, J. Benavides, et al. Neurochemical Characteristics of Amisulpride, an Atypical Dopamine D2/D3 Receptor Antagonist with Both Presynaptic and Limbic Selectivity J. Pharmacol. Exp. Ther., January 1, 1997; 280(1): 83 - 97. [Abstract] [Full Text]

				M. A. Moskowitz and C. Waeber Migraine Enters the Molecular Era Neuroscientist, May 1, 1996; 2(3): 191 - 200. [Abstract] [PDF]

				M. Skingle, N. Cole, G. Higgins, and W. Feniuk Inhibition of DOI-induced wet dog shakes in the guinea-pig by 5-HT2 receptor antagonists J Psychopharmacol, January 1, 1991; 5(3): 196 - 201. [Abstract] [PDF]

				M.D. Tricklebank Subtypes of 5-HT receptors J Psychopharmacol, January 1, 1987; 1(4): 222 - 226. [PDF]

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help